Published in AIDS Patient Care STDS on November 01, 2009
Mortality after diagnosis of psychiatric disorders and co-occurring substance use disorders among HIV-infected patients. AIDS Patient Care STDS (2010) 1.04
Serostatus disclosure among adults with HIV in the era of HIV therapy. AIDS Patient Care STDS (2011) 1.01
Validity of the Patient Health Questionnaire-9 to screen for depression in a high-HIV burden primary healthcare clinic in Johannesburg, South Africa. J Affect Disord (2014) 0.99
Association between race, depression, and antiretroviral therapy adherence in a low-income population with HIV infection. J Gen Intern Med (2012) 0.97
The interplay of sociodemographic factors on virologic suppression among a U.S. outpatient HIV clinic population. AIDS Patient Care STDS (2010) 0.97
Mental health of HIV-seropositive women during pregnancy and postpartum period: a comprehensive literature review. AIDS Behav (2014) 0.94
Routine depression screening in an HIV clinic cohort identifies patients with complex psychiatric co-morbidities who show significant response to treatment. AIDS Behav (2013) 0.92
Persistent HIV-related stigma among an outpatient US clinic population. Int J STD AIDS (2014) 0.90
Alcohol consumption is associated with poor health in HIV clinic patient population: a behavioral surveillance study. AIDS Behav (2011) 0.88
A consensus statement for safety monitoring guidelines of treatments for major depressive disorder. Aust N Z J Psychiatry (2011) 0.84
A randomized controlled trial of an HIV/AIDS Symptom Management Manual for depressive symptoms. AIDS Care (2012) 0.78
Depression severity is associated with increased risk behaviors and decreased CD4 cell counts. AIDS Care (2014) 0.78
Screening anxiety in the HIV clinic. AIDS Behav (2012) 0.77
The impact of depressive symptoms on patient-provider communication in HIV care. AIDS Care (2013) 0.76
Poor CD4 count is a predictor of untreated depression in human immunodeficiency virus-positive African-Americans. World J Psychiatry (2016) 0.75
Prevalence, Recurrence, and Incidence of Current Depressive Symptoms among People Living with HIV in Ontario, Canada: Results from the Ontario HIV Treatment Network Cohort Study. PLoS One (2016) 0.75
Implementation of PHQ-9 depression screening for HIV-infected patients in a real-world setting. J Assoc Nurses AIDS Care (2013) 0.75
Culturally Sensitive Approaches to Identification and Treatment of Depression among HIV Infected African American Adults: A Qualitative Study of Primary Care Providers' Perspectives. J Depress Anxiety (2016) 0.75
HIV-infected adolescent, young adult and pregnant smokers: important targets for effective tobacco control programs. Int J Environ Res Public Health (2013) 0.75
Patient characteristics and perceived health status of individuals with HIV and tuberculosis coinfection in Guangxi, China. Medicine (Baltimore) (2017) 0.75
The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med (2001) 76.04
Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA (2001) 5.52
Role of depression, stress, and trauma in HIV disease progression. Psychosom Med (2008) 3.65
Using the Patient Health Questionnaire-9 to measure depression among racially and ethnically diverse primary care patients. J Gen Intern Med (2006) 3.50
Discrimination, symptoms of depression, and self-rated health among african american women in detroit: results from a longitudinal analysis. Am J Public Health (2006) 2.97
Psychometric characteristics of the Scale for Suicide Ideation with psychiatric outpatients. Behav Res Ther (1997) 2.70
Validity/reliability of PHQ-9 and PHQ-2 depression scales among adults living with HIV/AIDS in western Kenya. J Gen Intern Med (2008) 2.45
Barriers to antiretroviral adherence: the importance of depression, abuse, and other traumatic events. AIDS Patient Care STDS (2006) 2.30
Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 2.02
Prevalence of DSM-IV-defined mood, anxiety, and substance use disorders in an HIV clinic in the Southeastern United States. J Acquir Immune Defic Syndr (2006) 2.01
Long-term risk for depressive symptoms after a medical diagnosis. Arch Intern Med (2005) 1.97
Risk for HIV infection among bisexual men seeking HIV-prevention services and risks posed to their female partners. Health Psychol (1998) 1.77
Social support, coping, and medication adherence among HIV-positive women with depression living in rural areas of the southeastern United States. AIDS Patient Care STDS (2007) 1.65
Predictors of employment of men with HIV/AIDS: a longitudinal study. Psychosom Med (2004) 1.54
The relationship of post-traumatic stress disorder and depression to antiretroviral medication adherence in persons with HIV. AIDS Patient Care STDS (2008) 1.48
Natural history of neuropsychiatric manifestations of HIV disease. Psychiatr Clin North Am (1994) 1.43
Depression and thoughts of suicide among middle-aged and older persons living with HIV-AIDS. Psychiatr Serv (2000) 1.41
The use of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection: impact on medical, palliative care, and quality of life outcomes. J Pain Symptom Manage (2001) 1.33
Effect of employment on quality of life and psychological functioning in patients with HIV/AIDS. Psychosomatics (2002) 1.31
Measuring desire for death among patients with HIV/AIDS: the schedule of attitudes toward hastened death. Am J Psychiatry (1999) 1.29
Psychiatric issues in the management of patients with HIV infection. JAMA (2001) 1.25
Prevalence and comorbidity of psychiatric diagnoses based on reference standard in an HIV+ patient population. Psychosom Med (2008) 1.19
Suicidal ideation, suicide attempts, and HIV infection. Psychosomatics (1998) 1.18
Correlates of perinatal depression in HIV-infected women. AIDS Patient Care STDS (2009) 1.18
Impact of depression on HIV outcomes in the HAART era. J Antimicrob Chemother (2008) 1.14
Effects of psychological interventions on neuroendocrine hormone regulation and immune status in HIV-positive persons: a review of randomized controlled trials. Psychosom Med (2008) 1.11
Psychosocial influences on HIV-1 disease progression: neural, endocrine, and virologic mechanisms. Psychosom Med (2008) 1.06
Disease severity, self-reported experience of workplace discrimination and employment loss during the course of chronic HIV disease: differences according to gender and education. Occup Environ Med (2007) 1.05
Association of race and gender with use of antiretroviral therapy among HIV-infected individuals in the Southeastern United States. South Med J (2007) 1.04
Symptoms of psychological distress among African Americans seeking HIV-related mental health care. AIDS Patient Care STDS (2008) 0.91
Psychological distress symptoms of individuals seeking HIV-related psychosocial support in western Kenya. AIDS Care (2007) 0.90
Disease severity and symptoms of depression in Black Americans infected with HIV. Appl Nurs Res (2001) 0.89
Integrating multidimensional HIV prevention programs into healthcare settings. Psychosom Med (2008) 0.89
Suicide probability and psychological morbidity secondary to HIV infection: a control study of HIV-seropositive, hepatitis C virus (HCV)-seropositive and HIV/HCV-seronegative injecting drug users. J Affect Disord (2001) 0.84
In vitro drug release studies on guar gum-based colon targeted oral drug delivery systems of 5-fluorouracil. Eur J Pharm Sci (2002) 1.51
Efficacy of newer medications for treating depression in primary care patients. Am J Med (2000) 1.49
Physicochemical characterization and dissolution properties of meloxicam-cyclodextrin binary systems. J Pharm Biomed Anal (2004) 1.45
Three-layer guar gum matrix tablet formulations for oral controlled delivery of highly soluble trimetazidine dihydrochloride. J Control Release (2002) 1.33
Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy. HIV Med (2006) 1.21
Factors associated with renal dysfunction within an urban HIV-infected cohort in the era of highly active antiretroviral therapy. HIV Med (2009) 1.21
Can you hear me now? Limited use of technology among an urban HIV-infected cohort. AIDS Care (2009) 1.17
Factors associated with prevalent abnormal anal cytology in a large cohort of HIV-infected adults in the United States. J Infect Dis (2010) 1.12
Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles. AAPS PharmSciTech (2007) 1.09
Yoga lifestyle intervention reduces blood pressure in HIV-infected adults with cardiovascular disease risk factors. HIV Med (2010) 1.08
In vivo pharmacokinetics in human volunteers: oral administered guar gum-based colon-targeted 5-fluorouracil tablets. Eur J Pharm Sci (2003) 1.07
Guar gum as a carrier for colon specific delivery; influence of metronidazole and tinidazole on in vitro release of albendazole from guar gum matrix tablets. J Pharm Pharm Sci (2001) 1.06
A three-layer guar gum matrix tablet for oral controlled delivery of highly soluble metoprolol tartrate. Int J Pharm (2002) 1.05
Studies on the development of oral colon targeted drug delivery systems for metronidazole in the treatment of amoebiasis. Int J Pharm (2002) 1.03
Pharmacokinetic evaluation of guar gum-based colon-targeted drug delivery systems of mebendazole in healthy volunteers. J Control Release (2003) 0.99
Lower peripheral blood CD14+ monocyte frequency and higher CD34+ progenitor cell frequency are associated with HBV vaccine induced response in HIV infected individuals. Vaccine (2011) 0.94
Treatment of depression--newer pharmacotherapies. Evid Rep Technol Assess (Summ) (1999) 0.93
Community level cancer control in a Texas barrio: Part I--Theoretical basis, implementation, and process evaluation. J Natl Cancer Inst Monogr (1995) 0.92
Management of chronic hypertension during pregnancy. Evid Rep Technol Assess (Summ) (2000) 0.91
Sub-optimal CD4 recovery on long-term suppressive highly active antiretroviral therapy is associated with favourable outcome. HIV Med (2009) 0.90
Are neighborhood conditions associated with HIV management? HIV Med (2013) 0.89
Studies on the development of colon-targeted delivery systems for celecoxib in the prevention of colorectal cancer. J Drug Target (2002) 0.87
Treatment of depression--newer pharmacotherapies. Psychopharmacol Bull (1998) 0.87
Effect of limonene on the in vitro permeation of nicardipine hydrochloride across the excised rat abdominal skin. Pharmazie (2002) 0.86
Predictors of immunity after hepatitis A vaccination in HIV-infected persons. J Viral Hepat (2007) 0.85
Design and in vitro evaluation of oral colon targeted drug delivery systems for tinidazole. J Drug Target (2002) 0.84
Studies on the development of colon targeted oral drug delivery systems for ornidazole in the treatment of amoebiasis. Drug Deliv (2003) 0.84
Penetration-enhancing effect of ethanol-water solvent system and ethanolic solution of carvone on transdermal permeability of nimodipine from HPMC gel across rat abdominal skin. Pharm Dev Technol (2004) 0.83
Development of colon targeted drug delivery systems for mebendazole. J Control Release (2001) 0.82
Bioavailability studies on guar gum-based three-layer matrix tablets of trimetazidine dihydrochloride in human volunteers. J Control Release (2002) 0.81
Influence of limonene on the bioavailability of nicardipine hydrochloride from membrane-moderated transdermal therapeutic systems in human volunteers. Int J Pharm (2002) 0.80
Formulation and evaluation of limonene-based membrane-moderated transdermal therapeutic system of nimodipine. Drug Deliv (2004) 0.79
In vivo evaluation of limonene-based transdermal therapeutic system of nicorandil in healthy human volunteers. Skin Pharmacol Physiol (2005) 0.79
Controlled in vivo release of nicorandil from a carvone-based transdermal therapeutic system in human volunteers. Drug Deliv (2006) 0.79
In vivo evaluation of guargum-based colon-targeted oral drug delivery systems of celecoxib in human volunteers. Eur J Drug Metab Pharmacokinet (2003) 0.79
Pharmacokinetic evaluation of guar gum-based three-layer matrix tablets for oral controlled delivery of highly soluble metoprolol tartrate as a model drug. Eur J Pharm Biopharm (2004) 0.79
Bioavailability of nerodilol-based transdermal therapeutic system of nicorandil in human volunteers. J Control Release (2005) 0.78
Effect of the solvent system on the in vitro permeability of nicardipine hydrochloride through excised rat epidermis. J Pharm Pharm Sci (2002) 0.78
In vitro and in vivo evaluation of guar gum-based matrix tablets of rofecoxib for colonic drug delivery. Curr Drug Deliv (2005) 0.78
HPLC determination of valproic acid in human serum. Pharmazie (2003) 0.77
Influence of menthol and pressure-sensitive adhesives on the in vivo performance of membrane-moderated transdermal therapeutic system of nicardipine hydrochloride in human volunteers. Eur J Pharm Biopharm (2003) 0.77
LC-MS/MS method for simultaneous estimation of candesartan and hydrochlorothiazide in human plasma and its use in clinical pharmacokinetics. Bioanalysis (2012) 0.77
Safety and tolerability of sequential pegylated IFN-alpha2a and tenofovir for hepatitis B infection in HIV(+) individuals. HIV Clin Trials (2007) 0.77
Granulomatous mastitis - a diagnostic dilemma. Indian J Surg (2008) 0.77
Enhanced percutaneous permeability of nicardipine hydrochloride by carvone across the rat abdominal skin. Drug Dev Ind Pharm (2003) 0.76
Penetration enhancing effect of menthol on the percutaneous flux of nicardipine hydrochloride through excised rat epidermis from hydroxypropyl cellulose gels. Pharm Dev Technol (2002) 0.76
In vitro percutaneous permeability enhancement of nimodipine by limonene across the excised rat abdominal skin. Pharmazie (2004) 0.76
Frailty and Pre-Frailty in a Contemporary Cohort of HIV-Infected Adults. J Frailty Aging (2014) 0.75
Effect of carvone on the permeation of nimodipine from a membrane-moderated transdermal therapeutic system. Pharmazie (2003) 0.75
Pharmacokinetic evaluation of guar gum-based colon-targeted drug delivery systems of tinidazole in healthy human volunteers. Drug Deliv (2003) 0.75
Reductimetric determination of peroxydisulphate, hydrogen peroxide, sodium perborate, nitrate and nitrite in concentrated phosphoric acid medium with iron(II). Talanta (1977) 0.75
Recurrent idiopathic polyneuropathy. J Indian Med Assoc (1974) 0.75
A validated RP-HPLC method for the determination of mosapride citrate in bulk drug samples and pharmaceutical formulations. Pharmazie (2002) 0.75
Communication techniques for patient instruction. Am J Hosp Pharm (1975) 0.75
Formulation and in vivo evaluation of membrane-moderated transdermal therapeutic systems of nicardipine hydrochloride using carvone as a penetration enhancer. Drug Deliv (2003) 0.75